May 3, 2023
Studies Find BioTissue Cryopreserved Amniotic Membrane Effective in Improving Outcomes of Pterygium, Cataract, and CCh Surgeries
Research Showcasing Benefits of BioTissue AmnioGraft and Prokera to be Presented at ASCRS 2023 in San Diego
MIAMI, May 2, 2023—Attendees at the 2023 ASCRS Annual Meeting this week can learn more about the latest research on surgical applications using cryopreserved amniotic membrane as part of the meeting’s scientific program. Among those advancements are papers and posters summarizing several investigator-initiated studies examining the efficacy of the BioTissue AmnioGraft® amniotic membrane surgical eye graft and Prokera® biologic corneal bandages.
“Physicians continue to realize the benefits of cryopreserved amniotic membrane to elevate the standard of care. BioTissue technology can help improve patient outcomes and save valuable time in the operating room,” said Scheffer C.G. Tseng, M.D., Ph.D., Founder and Chief Technology Officer, BioTissue. “It is exciting to see the multiple applications and advantages of our innovative products showcased in a range of research being presented at ASCRS.”
IMPROVED OUTCOMES & EFFICIENCY FOR PTERYGIUM SURGERY
Traditionally, pterygium surgery can be challenging, time-consuming, and often produces less-than-optimal results for the patient—including high rates of recurrence.
Neel R. Desai, M.D., who is among the nation’s foremost experts in ocular surface disease, conducted research examining outcomes of pterygium excision surgery using the TissueTuck sutureless technique with BioTissue AmnioGraft cryopreserved amniotic membrane. Findings suggest a low risk of recurrence and complications in cases of recurrent pterygium. Dr. Desai will present his paper, Outcomes of the TissueTuck Surgical Technique for Recurrent Pterygium, on Saturday, May 6 at 1:40 p.m. in Room 1B.
Dr. Desai’s Cryopreserved Amniotic Membrane during Pterygium Excision: Health Economic Opportunity Analysis poster compares the average surgical duration and cost of pterygium surgery using the TissueTuck technique with pterygium surgery using conjunctival autograft. An additional paper on the topic, Retrospective Review of Pterygium Surgery with Cryopreserved Amniotic Membrane, will be presented by Jose Quiceno, M.D., on Saturday, May 6 at 1:55 p.m. in Room 1B.
OCULAR SURFACE OPTIMIZATION & RECONSTRUCTION
Outcomes after cataract surgery can be compromised by dry eye disease. In Ocular Surface Optimization with Cryopreserved Amniotic Membrane Prior to Cataract Surgery, Jeff Wongs, M.D., explores whether BioTissue Prokera biologic corneal bandages can sufficiently stabilize the ocular surface to improve accuracy of intraocular lens calculations and ultimately, post-operative outcomes for patients with moderate to severe dry eye disease. Dr. Wongs will present his findings on Sunday, May 7 at 8:30 a.m. in Room 1A.
BioTissue AmnioGraft cryopreserved amniotic membrane is also the focus of a study assessing the outcomes of ocular surface reconstruction surgery using the product in patients with conjunctivochalasis (CCh). Findings of Retrospective Review of Conjunctivochalasis Surgery with Cryopreserved Amniotic Membrane conclude that surgical treatment of CCh using the reservoir restoration procedure with AmnioGraft is safe and helps to restore tear film dynamics. This reduction in CCh severity was also accompanied with improvement in patient symptoms and corneal staining. The poster, prepared by principal investigator Jose Quiceno, M.D., will be on display throughout the conference.
For more information about ASCRS 2023, including a full schedule of paper and poster presentations, visit annualmeeting.ascrs.org.
About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues biologics license applications for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 790,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.
McDougall Communications for BioTissue
[email protected] or (585) 434-2148